Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mirati Therapeutics
(NQ:
MRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mirati Therapeutics
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
November 08, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
October 17, 2023
Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to...
Via
PressReach
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Investor Alert: Investigation over Possible Breaches of Fiduciary Duties
May 11, 2023
San Diego, CA -- (SBWIRE) -- 05/11/2023 -- Certain directors of Mirati Therapeutics, Inc are under investigation over potential breaches of fiduciary duties.
Via
SBWire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE
October 16, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
October 10, 2023
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...
Via
PressReach
MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
October 09, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasdaq - SP), Summit Materials (NYSE - SUM)
October 09, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
MRTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mirati Therapeutics, Inc. Is Fair to Shareholders
October 08, 2023
From
Halper Sadeh LLC
Via
Business Wire
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
October 08, 2023
From
Bristol Myers Squibb
Via
Business Wire
Pancreatic Cancer Battle Boosted by $200M VC Firm
September 19, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs
June 22, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:POAI),(NASDAQ:AGLE),(NASDAQ:TALS),(NASDAQ:MRTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
November 15, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
November 07, 2022
From
Incyte and Mirati
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Mirati Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
June 16, 2022
From
The Schall Law Firm
Via
Business Wire
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
December 10, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Investigation Announced for Long-Term Investors in Mirati Therapeutics, Inc. (NASDAQ:MRTX)
December 07, 2021
San Diego, CA -- (SBWIRE) -- 12/07/2021 -- Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
November 22, 2021
From
Verastem Oncology
Via
Business Wire
NASDAQ:MRTX Investor Notice: Investigation over Possible Securities Laws Violations by Mirati Therapeutics, Inc.
November 08, 2021
San Diego, CA -- (SBWIRE) -- 11/08/2021 -- Mirati Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
May 25, 2021
From
QIAGEN N.V.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.